Interferons in relapsing remitting multiple sclerosis

[...]exclusion of the small trials of interferon alfa made little difference to our result (relative risk of exacerbation at 1 year 0.79, 95% CI 0.58–1.07). Neither univariate nor multivariate meta-regression analysis of treatment in the first year showed significant effects for dose (p=0.222), type...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2003-05, Vol.361 (9371), p.1823-1824
Main Authors: Filippini, Graziella, Munari, Luca, Ebers, George C, D'Amico, Roberto, Rice, George PA
Format: Article
Language:English
Subjects:
Interferon
Multiple sclerosis
Regression analysis
Sensitivity analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]exclusion of the small trials of interferon alfa made little difference to our result (relative risk of exacerbation at 1 year 0.79, 95% CI 0.58–1.07). Neither univariate nor multivariate meta-regression analysis of treatment in the first year showed significant effects for dose (p=0.222), type of interferon (p=0.427), or duration of treatment (p=0.260). Goodin's suggestion to disregard MSCRG was contrary to our protocol.1 Moreover, MSCRG was used for the registration of Biogen's interferon beta-1a (Avonex), the most widely-used interferon in the USA.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(03)13420-4